Supernus Pharmaceuticals Posts Record Q4 2025 Revenue Growth
Supernus Pharmaceuticals reported record revenue growth in Q4 2025 during its earnings call, marking its highest quarterly sales to date. Management highlighted robust demand across its neurology portfolio driving year-over-year top-line expansion.
1. Q4 2025 Performance
Supernus Pharmaceuticals closed Q4 2025 with record revenue, surpassing previous quarterly highs. The company attributed the milestone to elevated demand and execution across its therapeutic offerings.
2. Product Portfolio Drivers
Management emphasized strong sales momentum in its neurology portfolio, noting that key brands delivered year-over-year gains. Leadership cited continued patient adoption as a catalyst for top-line strength.
Related News
INTC
Nvidia’s $91B AI Forecast, $80B Buyback Ramps Up Pressure on Intel
INTC•
NVO
Novo Nordisk Shares Slump 45% to 10x P/E as Pharma Fuels Danish GDP
NVO•
JEPI
Active ETFs Shift Holdings Daily, Provide Downside Protection, Charge 0.4%-1% Fees
JEPI•
QQQ
Nasdaq-100 ETF Trackers Eye 30% EM Earnings Growth and Nvidia’s $78.8B Quarter
QQQ•
NVDA
Nvidia’s AI Chip Revenue Forecast Beats Estimates but Shares Drop 1.3%
NVDA•
Sources
F